Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial. “New novel therapies ...

SLS and ATNM are heading into the AACR summit with fresh leukemia-focused data catalysts expected to refocus investor attention. ・Sellas will present preclinical AML data on SLS009, demonstrating ...

Anticipated updates on the company’s leukemia drug SLS009 did not land, dampening near-term catalyst momentum. ・Earlier studies showed SLS009 triggered leukemia cell death and remained active in ...

Computer extracted features on H&E images to improve biochemical recurrence prediction of Kattan nomogram for prostate cancer patients following radical prostatectomy: Preliminary findings. This is an ...

Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free ...

The TP53 gene provides instructions for making a protein called tumor protein p53 (or p53). This protein regulates cell division by keeping cells from growing and dividing too fast or in an ...

In a recent study published in Nature Genetics, researchers performed an allelic-level single-cellular multi-omics evaluation of hematopoietic stem/progenitor cells (HSPCs) obtained from individuals ...

—A study of 1230 individuals with chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis demonstrated that patients with wild type TP53 had longer time to first treatment and ...

Considered the "guardian of the genome," TP53 is the most commonly mutated gene in cancer. TP53's normal function is to detect DNA damage and prevent cells from passing this damage on to daughter ...